Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
The division is expected to grow to over a 100-member strong team by 2022
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
The company claims that its Empagliflozin tablets are the most affordable in India
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Subscribe To Our Newsletter & Stay Updated
